BIOMX
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
BIOMX
Industry:
Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Ness Ziona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.biomx.com
Total Employee:
11+
Status:
Active
Contact:
+97289553100
Email Addresses:
[email protected]
Total Funding:
74 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-12-19 | RondinX | RondinX acquired by BIOMx | N/A |
Investors List
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Post-IPO Equity - BIOMx
8VC
8VC investment in Series B - BIOMx
Handok
Handok investment in Series B - BIOMx
SBI Japan-Israel Innovation Fund
SBI Japan-Israel Innovation Fund investment in Series B - BIOMx
Chong Kun Dang Pharmaceutical Corp.
Chong Kun Dang Pharmaceutical Corp. investment in Series B - BIOMx
Johnson & Johnson Innovation
Johnson & Johnson Innovation investment in Series B - BIOMx
Takeda Ventures
Takeda Ventures investment in Series B - BIOMx
OrbiMed
OrbiMed investment in Series B - BIOMx
Seventure Partners
Seventure Partners investment in Series B - BIOMx
KB Investment
KB Investment investment in Series B - BIOMx
Official Site Inspections
http://www.biomx.com Semrush global rank: 3.59 M Semrush visits lastest month: 4 K
- Host name: 104.21.37.10
- IP address: 104.21.37.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BIOMx"
About - Biomx
Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative …See details»
Company Information :: BiomX, Inc. (PHGE)
BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as …See details»
BIOMx - Crunchbase Company Profile & Funding
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's …See details»
Board of Directors :: BiomX, Inc. (PHGE)
Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. ... supporting the company’s IPO and …See details»
BiomX, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
BiomX ContactsInvestor Relations:LifeSci Advisors, LLCJohn FrauncesManaging Director(917) [email protected], orBrian MullenLifeSci Advisors, LLC(203) 461 …See details»
BiomX Inc - LinkedIn
BiomX Inc | 6,613 followers on LinkedIn. Customized phage therapies to eradicate harmful bacteria in chronic diseases | BiomX is developing both natural and engineered phage cocktails designed to ...See details»
BiomX Inc. (PHGE) Company Profile & Overview - Stock Analysis
5 days ago BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful …See details»
BiomX - Overview, News & Similar companies | ZoomInfo.com
Who is BiomX. BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic …See details»
BIOMx - Funding, Financials, Valuation & Investors - Crunchbase
BIOMx is registered under the ticker NYSEMKT:PHGE . BIOMx is funded by 16 investors. Cystic Fibrosis Foundation and OrbiMed are the most recent investors. BIOMx has acquired 2 …See details»
BiomX Inc. Announces $15 Million Registered Direct Offering
NESS ZIONA, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel …See details»
Board Committees :: BiomX, Inc. (PHGE)
He previously served as a member of the Executive Committee of the Board of the National Venture Capital Association (NVCA), where he led NVCA’s life sciences industry efforts as …See details»
BiomX Announces the Appointment of Susan Blum to its Board of …
Apr 18, 2024 For more information, please visit www.biomx.com, the content of which does not form a part of this press release. BiomX Contacts. Investor Relations: LifeSci Advisors, LLC …See details»
Careers - Biomx
WHAT DOES IT MEAN TO BE A PART OF BIOMX? We share a sense of purpose across the organization, with every role. We cultivate and build upon industry-leading, global expertise. …See details»
BiomX Inc. (PHGE) Stock Price, News, Quote & History - Yahoo …
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated …See details»
Technology - Biomx
Biomx’s corporate presentation Updated September 2024. Sign up for the latest updates Join our mailing list to receive company updates delivered to your inbox Join the list. Reach Us. 708 …See details»
BiomX Announces Entry into Merger Agreement with Adaptive …
Mar 6, 2024 About BX004 BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main …See details»
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results …
Apr 3, 2024 About BX004 BiomX is developing BX004, a fixed multi-phage cocktail, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main …See details»
Our Pipeline - Biomx
We have entered into two collaborations with Boehringer Ingelheim. Our first collaboration with Boehringer Ingelheim was announced in September 2020 (see press release) utilizes the …See details»
Newsroom - Biomx
Mar 6, 2024 The Pharma Letter - BiomX announces Adaptive merger and financing. Mar 6, 2024 FierceBiotech - BiomX acquires fellow bacteria-killing virus company Adaptive Phage to …See details»